Healthcare

IDT Australia Ltd (ASX:IDT) shares moved 4.88% higher to AUD 0.043 during the morning session on 28 April 2026, following the release of its March quarter update and revised FY26 guidance. While the stock remains down 60.91% over the past year, the latest update …

Island Pharmaceuticals Ltd (ASX:ILA) shares edged higher in Monday’s session, rising 1.33% to AUD 0.38 on 27 April 2026, as investors responded to the company’s March 2026 quarterly activities report. The update highlighted significant regulatory progress for its Galidesivir antiviral program, alongside strengthened funding …

Noxopharm Limited (ASX:NOX) traded flat at AUD 0.076 on 27 April 2026, with no immediate price movement despite the announcement of new preclinical results related to its Sofra platform. The stock remains approximately 5% lower over the past year, reflecting a broader period of …

Clinuvel Pharmaceuticals Ltd (ASX:CUV) shares edged 0.55% lower to AUD 8.99 during the afternoon session on 27 April 2026, despite the company announcing a regulatory update from the U.S. Food and Drug Administration (FDA) relating to its lead therapy SCENESSE. While the stock remains …

Chimeric Therapeutics (ASX:CHM) is an Australian clinical-stage biotechnology company specializing in cell therapy for oncology. The company’s portfolio encompasses both autologous CAR T-cell therapies and allogeneic natural killer (NK) cell therapies, targeting hematologic malignancies and solid tumors. With four clinical-stage programs currently underway, Chimeric …

Island Pharmaceuticals (ASX:ILA) rose 1.33% to AUD 0.38 on 27 April 2026, with the gain drawing attention to a quarterly update centred on regulatory alignment, strategic partnerships and capital support for its Galidesivir antiviral program. While the share price rise was not outsized, the …

PYC Therapeutics (ASX:PYC) rose 0.39% to AUD 1.30 on 27 April 2026 as investors responded to a regulatory milestone that added another layer to the company’s lead clinical program. While the share price move was modest, market attention appeared centred less on the size …